Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Orbis Medicines | 2025 | Series A | $93.2M | Frederiksberg |
| Nuvig Therapeutics | 2024 | Series B | $161.0M | Redwood City |
| Convergent Therapeutics | 2024 | Series A | $40.0M | Cambridge |
| Reduced | 2024 | Series A | $8.9M | Copenhagen |
| Kebotix | 2024 | Venture - Series Unknown | $5.0M | Cambridge |
| Draupnir Bio | 2024 | Seed | $13.2M | Risskov |
| Myricx Bio | 2024 | Series A | $115.3M | London |
| CIRCTEC | 2024 | Venture - Series Unknown | $162.8M | London |
| Bluejay Therapeutics | 2024 | Series C | $182.0M | San Mateo |
| Asgard Therapeutics | 2024 | Series A | $32.6M | Lund |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Orbis Medicines | Series A | $93.2M | Frederiksberg, Denmark |
| 27 | Nuvig Therapeutics | Series B | $161.0M | Redwood City, United States |
| 28 | Convergent Therapeutics | Series A | $40.0M | Cambridge, United States |
| 29 | Reduced | Series A | $8.9M | Copenhagen, Denmark |
| 30 | Kebotix | Venture - Series Unknown | $5.0M | Cambridge, United States |
| 31 | Draupnir Bio | Seed | $13.2M | Risskov, Denmark |
| 32 | Myricx Bio | Series A | $115.3M | London, United Kingdom |
| 33 | CIRCTEC | Venture - Series Unknown | $162.8M | London, United Kingdom |
| 34 | Bluejay Therapeutics | Series C | $182.0M | San Mateo, United States |
| 35 | Asgard Therapeutics | Series A | $32.6M | Lund, Sweden |
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
Reduced develops natural flavor enhancers from upcycled produce.
Kebotix is a high-tech materials discovery and production company that reinvent the discovery of new materials using AI.
Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
CIRCTEC is an innovator and operator of pyrolysis technology to recycle waste into renewable fuels and circular chemicals.
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.
Asgard Therapeutics is a Biotechnology Company.
Octave provides mental health care that's both accessible to people and sustainable for providers.
Nalu Medical is a medical technology company that develops innovative solutions for patients with chronic neuropathic pain.
Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Doctor Anywhere is a telehealth company .
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Pioneering the market introduction of powerful, autonomous, safe and eco-friendly water and air treatment solutions.
Clever Care Health Plan is a healthcare company that offers medicare advantage health plans to its members.
Chromologics develops innovative natural food colorants.
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.
Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.
Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases.
Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Bactolife is a biotechnology company that develops biological solutions to support gut health.
Novo Holdings has invested in 154 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novo Holdings's top investment sectors include Health Care, Biotechnology, Medical, Pharmaceutical, Therapeutics. The firm invests across 32 different industry categories.
Among tracked funding rounds, Praxis Precision Medicines received $575.0M in a Post Ipo Equity round. Novo Holdings's total known invested capital is $9.7B.
Novo Holdings's average investment size is $85.4M across its portfolio of 154 companies.
Recent Novo Holdings portfolio additions include Orbis Medicines, Nuvig Therapeutics, Convergent Therapeutics, Reduced, Kebotix. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors